Your browser doesn't support javascript.
loading
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Lee, Nancy; Harris, Jonathan; Garden, Adam S; Straube, William; Glisson, Bonnie; Xia, Ping; Bosch, Walter; Morrison, William H; Quivey, Jeanne; Thorstad, Wade; Jones, Christopher; Ang, K Kian.
Afiliação
  • Lee N; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10021, USA. leen2@mskcc.org
J Clin Oncol ; 27(22): 3684-90, 2009 Aug 01.
Article em En | MEDLINE | ID: mdl-19564532
ABSTRACT

PURPOSE:

To investigate the feasibility of intensity-modulated radiation therapy (IMRT) with or without chemotherapy, and to assess toxicities, failure patterns, and survivals in patients with nasopharyngeal carcinoma (NPC). PATIENTS AND

METHODS:

Radiation consisted of 70 Gy given to the planning target volumes of primary tumor plus any N+ disease and 59.4 Gy given to subclinical disease, delivered over 33 treatment days. Patients with stage T2b or greater or with N+ disease also received concurrent cisplatin (100 mg/m(2)) on days 1, 22, and 43 followed by adjuvant cisplatin (80 mg/m(2)) on day 1; fluorouracil (1,000 mg/m(2)/d) on days 1 through 4 administered every 4 weeks for three cycles. Tumor, clinical status, and acute/late toxicities were assessed. The primary objective was to test the transportability of IMRT to a multi-institutional setting.

RESULTS:

Between February 2003 and November 2005, 68 patients with stages I through IVB NPC (of which 93.8% were WHO types 2 and 3) were enrolled. Prescribed IMRT (target delineation) was given to 83.8%, whereas 64.9% received chemotherapy per protocol. The estimated 2-year local progression-free (PF), regional PF, locoregional PF, and distant metastasis-free rates were 92.6%, 90.8%, 89.3%, and 84.7%, respectively. The estimated 2-year PF and overall survivals were 72.7% and 80.2%, respectively. Acute grade 4 mucositis occurred in 4.4%, and the worst late grade 3 toxicities were as follows esophagus, 4.7%; mucous membranes, 3.1%; and xerostomia, 3.1%. The rate of grade 2 xerostomia at 1 year from start of IMRT was 13.5%. Only two patients complained of grade 3 xerostomia, and none had grade 4 xerostomia.

CONCLUSION:

It was feasible to transport IMRT with or without chemotherapy in the treatment of NPC to a multi-institutional setting with 90% LRPF rate reproducing excellent reports from single institutions. Minimal grade 3 and lack of grade 4 xerostomia were encouraging.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lesões por Radiação / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Nasofaríngeas / Radioterapia de Intensidade Modulada Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lesões por Radiação / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Nasofaríngeas / Radioterapia de Intensidade Modulada Idioma: En Ano de publicação: 2009 Tipo de documento: Article